首页 /药靶模型 /药靶细胞 /免疫治疗 /PDL1/aAPC/Raji

PDL1/aAPC/Raji

CBP74145

询 价
索取Protocol
产品描述
产品数据库
I. Background
      Programmed Cell Death Protein 1 (PD-1),一种在激活的 T 细胞上表达的受体,与其配体 PD-L1 和 PD-L2 结合,负向调节免疫反应。 PD-1 配体存在于大多数癌症中,PD-1:PD-L1/2 相互作用会抑制 T 细胞活性,并使癌细胞逃避免疫监视。 PD1/PDL1信号转导通路是肿瘤免疫抑制的重要组成部分,可以抑制T淋巴细胞的兴奋,增强肿瘤细胞的免疫耐受,从而实现肿瘤免疫逃逸。
 
II. Introduction
Expressed gene: PD-L1、aAPC
Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium: 90% FBS+10% DMSO
Culture Medium: RPMI-1640+10%FBS+1ug/ml puromycin+200ug/ml hygromycin
Mycoplasma Testing: Negative
Storage: Liquid nitrogen
Application(s): Functional(Report Gene) Assay
 
III. Representative Data

Figure 1. Dose Response of Anti-PD-L1 Blocking Antibody in PD-1-IL2 Pathway Effector Reporter Cells (C37) With Raji PD-L1 aAPC Cells.

 

Figure 2. Dose Response of Anti-PD-1 Blocking Antibody in PD-1-IL2 Pathway Effector Reporter Cells (C37) With Raji PD-L1 aAPC Cells.

药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交